MedTrace Logo

A Study of SHR-A1904 in Previous Systemic Treatment Failed Biliary Tract Cancer

NCT07450976 · Status: RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 151

Last updated 2026-03-31

No results posted yet for this study

Summary

This is a multicenter, Phase 2 clinical trial to evaluate the efficacy and safety, PK and immunogenicity of SHR-A1904 in patients with advanced or metastatic biliary tract cancer (BTC). Patients will treat with SHR-A1904 until unacceptable toxicity or disease progression.

Conditions

  • Biliary Tract Cancer

Interventions

DRUG

SHR-A1904 for Injection

SHR-A1904 for injection, different doses.

Sponsors & Collaborators

  • Suzhou Suncadia Biopharmaceuticals Co., Ltd.

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-03-25
Primary Completion
2030-12-31
Completion
2030-12-31

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07450976 on ClinicalTrials.gov